Litcius/Paper detail

1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)

Geoffrey Y. Ku, Elena Elimova, C.S. Denlinger, Ram Sharan Mehta, Kyung-Woo Lee, Syma Iqbal, Y-K. Kang, D. Oh, Sun Young Rha, Yeul Hong Kim, Young Mi Seol, T. Mwatha, J. Grim, Jaffer A. Ajani

2021Annals of Oncology31 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInternal medicineHypokalemiaOxaliplatinGastroenterologyVomitingNauseaCapecitabineAdverse effectCancerColorectal cancerHER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesPeptidase Inhibition and Analysis
1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA) | Litcius